Maire A. Duggan

Maire A. Duggan

Auto-generated profile, based on publicly available information

Maire A. Duggan

Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TZTongwu Zhang
Tongwu Zhang
Philippe JoubertPhilippe Joubert
Philippe Joubert
NANaser Ansari-Pour
Naser Ansari-Pour
WZWei Zhao
Wei Zhao
PHPhuc Huu Hoang
Phuc Huu Hoang
MLMaria Teresa Landi
Maria Teresa Landi

3 August 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JFJonine D. Figueroa
Jonine D. Figueroa
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
LBLouise A. Brinton
Louise A. Brinton
MPMaya M. Palakal
Maya M. Palakal
ADAmy C. Degnim
Amy C. Degnim
MSMark E. Sherman
Mark E. Sherman

2 June 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
TAThomas Ahearn
Thomas Ahearn
PCParichoy Pal Choudhury
Parichoy Pal Choudhury
ADAndriy Derkach
Andriy Derkach
BWBeatrice Wiafe-Addai
Beatrice Wiafe-Addai
BABaffour Awuah
Baffour Awuah
MGMontserrat Garcia-Closas
Montserrat Garcia-Closas
Background: Risk estimates for women carrying germline mutations in breast cancer susceptibility genes are mainly based on studies of European ancestry women. Methods: We investigated associations between pathogenic variants (PV) in 34 genes with breast cancer risk in 871 cases [307 estrogen receptor (ER)-positive, 321 ER-negative, and 243 ER-unknown] and 1,563 controls in the Ghana Breast Health Study (GBHS), and estimated lifetime risk for carriers. We compared results with those for European, Asian, and African American ancestry women. Results: The frequency of PV in GBHS for nine breast cancer genes was 8.38% in cases and 1.22% in controls. Relative risk estimates for overall breast cancer were: (OR, 13.70; 95% confidence interval (CI), 4.03–46.51) for BRCA1, (OR, 7.02; 95% CI, 3.17–15.54) for BRCA2, (OR, 17.25; 95% CI, 2.15–138.13) for PALB2, 5 cases and no controls carried TP53 PVs, and 2.10, (0.72–6.14) for moderate-risk genes combined (ATM, BARD1, CHEK2, RAD51C, RAD52D). These estimates were similar to those previously reported in other populations and were modified by ER status. No other genes evaluated had mutations associated at P < 0.05 with overall risk. The estimated lifetime risks for mutation carriers in BRCA1, BRCA2, and PALB2 and moderate-risk genes were 18.4%, 9.8%, 22.4%, and 3.1%, respectively, markedly lower than in Western populations with higher baseline risks. Conclusions: We confirmed associations between PV and breast cancer risk in Ghanaian women and provide absolute risk estimates that could inform counseling in Ghana and other West African countries. Impact: These findings have direct relevance for breast cancer genetic counseling for women in West Africa.

1 January 2014 in Gynecologic Oncology
Verified
Journal Article
Closed access
JMJohn B. McIntyre
John B. McIntyre
GNGregg Nelson
Gregg Nelson
PGPrafull Ghatage
Prafull Ghatage
DMDon G. Morris
Don G. Morris
MDMáire A. Duggan
Máire A. Duggan
MKMartin Köbel
Martin Köbel

1 November 2013 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
NBNicole Bures
Nicole Bures
GNGregg Nelson
Gregg Nelson
QDQiuli M.Sc. Duan
Qiuli M.Sc. Duan
AMAnthony M.D. Magliocco
Anthony M.D. Magliocco
DDDoug M.D. Demetrick
Doug M.D. Demetrick
MDMáire A. M.D. Duggan
Máire A. M.D. Duggan
Molecular alterations leading to cell cycle dysregulation in primary squamous cell carcinoma of the endometrium (PSCCE) and correlation with clinical outcome are incompletely described. Molecular variables of 5 cases of PSCCE were compared with 8 controls of endometrial endometrioid adenocarcinoma and correlated with overall survival. Immunohistochemical expression of pRB, p18, p19, CDK4, CDK6, Cyclin D1, p16, HPVE7, pTEN, ER, PR, and p53 was independently scored (intensity: 0–3 and proportion: 0–5) twice by 2 reviewers. Scores were averaged and expression was categorized as positive or negative. Human papillomavirus (HPV) DNA amplification and Braf and Kras mutations were assessed by polymerase chain reaction. Distribution differences between cases and controls were tested for significance using χ2/Fisher exact tests. Differences in overall survival and correlation with variables were calculated using Kaplan-Meier and tested for significance using log rank tests. All cases and controls were mostly positive for pRB, p19, CDK6, and Cyclin D1 and mostly negative for p16, p18, CDK4, HPVE7, pTEN, and p53. Cases were mostly negative for ER and PR, whereas controls were mostly positive. All were negative for HPV DNA amplification and Braf mutations. One case and 2 controls had a Kras mutation. Only the ER and PR distribution difference was significant (P=0.03 and 0.02, respectively) and differences in overall survival did not correlate with any variable. PSCCE has molecular alterations involving the pRB-Cyclin D1-CDK4/6-p16 pathway, and pTEN. In contrast to the type I EACC, PSCCE is not hormonally sensitive, suggesting a unique pathogenesis.

6 February 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
MAMustapha Abubakar
Mustapha Abubakar
SFShaoqi Fan
Shaoqi Fan
EBErin Aiello Bowles
Erin Aiello Bowles
LWLea Widemann
Lea Widemann
MDMáire A Duggan
Máire A Duggan
GGGretchen L. Gierach
Gretchen L. Gierach
Benign breast disease (BBD) is a strong breast cancer risk factor, but identifying patients that might develop invasive breast cancer remains a challenge. By applying machine-learning to digitized hematoxylin and eosin–stained biopsies and computer-assisted thresholding to mammograms obtained circa BBD diagnosis, we generated quantitative tissue composition metrics and determined their association with future invasive breast cancer diagnosis. Archival breast biopsies and mammograms were obtained for women (18-86 years of age) in a case-control study, nested within a cohort of 15 395 BBD patients from Kaiser Permanente Northwest (1970-2012), followed through mid-2015. Patients who developed incident invasive breast cancer (ie, cases; n = 514) and those who did not (ie, controls; n = 514) were matched on BBD diagnosis age and plan membership duration. All statistical tests were 2-sided. Increasing epithelial area on the BBD biopsy was associated with increasing breast cancer risk (odds ratio [OR]Q4 vs Q1 = 1.85, 95% confidence interval [CI] = 1.13 to 3.04; Ptrend = .02). Conversely, increasing stroma was associated with decreased risk in nonproliferative, but not proliferative, BBD (Pheterogeneity = .002). Increasing epithelium-to-stroma proportion (ORQ4 vs Q1 = 2.06, 95% CI =1.28 to 3.33; Ptrend = .002) and percent mammographic density (MBD) (ORQ4 vs Q1 = 2.20, 95% CI = 1.20 to 4.03; Ptrend = .01) were independently and strongly predictive of increased breast cancer risk. In combination, women with high epithelium-to-stroma proportion and high MBD had substantially higher risk than those with low epithelium-to-stroma proportion and low MBD (OR = 2.27, 95% CI = 1.27 to 4.06; Ptrend = .005), particularly among women with nonproliferative (Ptrend = .01) vs proliferative (Ptrend = .33) BBD. Among BBD patients, increasing epithelium-to-stroma proportion on BBD biopsies and percent MBD at BBD diagnosis were independently and jointly associated with increasing breast cancer risk. These findings were particularly striking for women with nonproliferative disease (comprising approximately 70% of all BBD patients), for whom relevant predictive biomarkers are lacking.